Sumitomo Pharma Co., Ltd. Logo

Sumitomo Pharma Co., Ltd.

R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.

4506 | T

Overview

Corporate Details

ISIN(s):
JP3495000006
LEI:
Country:
Japan
Address:
大阪市中央区道修町2丁目6番8号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sumitomo Pharma Co., Ltd. is a research and development-oriented pharmaceutical company focused on creating innovative medicines and healthcare solutions. The company concentrates its R&D and commercial activities in the therapeutic areas of oncology, psychiatry, and neurology. It develops treatments across various modalities, including small molecules, regenerative medicine, and cell therapy. Sumitomo Pharma operates with global business platforms, with a strategic focus on Japan and the United States as its primary markets. The company's mission is to contribute to the betterment of healthcare and fuller lives for people worldwide by translating scientific innovation into real-world solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 08:19
Registration Form
確認書
Japanese 8.7 KB
2025-11-04 08:13
Interim Report
半期報告書-第206期(2025/04/01-2025/09/30)
Japanese 319.2 KB
2025-10-31 08:39
M&A Activity
訂正臨時報告書
Japanese 41.0 KB
2025-06-27 09:05
Post-Annual General Meeting Information
臨時報告書
Japanese 29.6 KB
2025-06-26 09:39
Registration Form
確認書
Japanese 8.7 KB
2025-06-26 09:36
Governance Information
内部統制報告書-第205期(2024/04/01-2025/03/31)
Japanese 24.0 KB
2025-06-26 09:31
Annual Report
有価証券報告書-第205期(2024/04/01-2025/03/31)
Japanese 2.1 MB
2025-05-30 09:41
M&A Activity
訂正臨時報告書
Japanese 40.7 KB
2025-05-14 09:18
M&A Activity
訂正臨時報告書
Japanese 36.6 KB
2025-04-28 10:06
Regulatory News Service
訂正臨時報告書
Japanese 24.3 KB
2025-04-28 10:03
Regulatory News Service
臨時報告書
Japanese 19.0 KB
2025-04-03 09:39
M&A Activity
臨時報告書
Japanese 41.7 KB
2025-01-31 08:11
Regulatory News Service
臨時報告書
Japanese 18.7 KB
2024-12-19 07:19
Regulatory News Service
臨時報告書
Japanese 19.2 KB
2024-11-01 03:30
Interim Report
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Sumitomo Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sumitomo Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sumitomo Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB

Talk to a Data Expert

Have a question? We'll get back to you promptly.